Psychoplastogens, CAR-T and gene therapies show innovation in action, says EFPIA

Some of the most exciting medical breakthroughs in development have been picked out by the European Federation of Pharmaceutical Industries and Associations (EFPIA) as evidence of the sector’s progress.

As part of a blog post, the trade group’s executive director for strategy and healthcare systems, Thomas Allvin, has highlighted a few types of treatments in development from EFPIA’s 2022 Pipeline Review to show research and innovation in action and how it is responding to patient need.

His first example comes in the field of depression, a mental health conditions impacting more than 31 million Europeans, according to estimates. In some countries, close to one in eight people are afflicted, a number believed to have been exacerbated by COVID-19.